NL-OMON53695RecruitingNot Applicable
SerUM markers in MERkel Cell Carcinoma patients: a longitudinal moniTorIng study for optiMization of European guidelines. - SUMMERTIME
niversity Hospital Center of Tours0 sites10 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 10
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1) Patients with a « de novo » diagnosis of MCC, confirmed on
- •histological criteria (neuroendocrine morphology, CK20 staining
- •and/or neuroendocrine and/or SATB2 staining, exclusion of
- •differential diagnosis)
- •2) >= 18 years of age
- •3) Written informed consent obtained from the participant
Exclusion Criteria
- •1) Patients following any measures of legal presentation
- •2) Pregnancy or breastfeeding
Investigators
Similar Trials
Active, not recruiting
Not Applicable
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European GuidelinesMerkel Cell CarcinomaNCT04705389University Hospital, Tours35
Active, not recruiting
Not Applicable
Blood testing to predict good response to chemotherapyCTRI/2020/10/028763AIIMS
Completed
Not Applicable
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory studyNon-small cell lung cancer (NSCLC)10038666NL-OMON45880niversitair Medisch Centrum Groningen40
Not yet recruiting
Not Applicable
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung canceron-small cell lung cancer, KRAS mutationNiet-kleincellig longkanker, KRAS mutatieNL-OMON25545niversity Medical Center Groningen40
Enrolling By Invitation
Not Applicable
Correlation between serum squamous cell carcinoma antigen level and c-reactive protein with tumor volume in oral cavity cancerAdult patients (18-80 years) with oral cavity squamous cell carcinomaSquamous cell carcinoma antigen, CRP, Tumor volume, Oral cavity cancerTCTR20211002001/A30